Nicholas Dutro, MD
Family Medicine · Fort Wayne, INNPI 1992024327
Payments from drug & device makers
Across 121 payments — averaging $35.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Lilly USA, LLC$416
- AbbVie$391
- Novo Nordisk$230
- Astellas Pharma US Inc$152
- GSK$110
- plus $567 from 15 others
What the payments were for
- Consulting fees$3508%
- Speaking & faculty fees$1,96046%
- Food & beverage$1,93646%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 10 | $2,380 |
| Lilly USA, LLC | 26 | $416 |
| AbbVie | 23 | $391 |
| Novo Nordisk | 14 | $230 |
| Astellas Pharma US Inc | 6 | $152 |
| GSK | 8 | $110 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $88 |
| AstraZeneca | 4 | $63 |
| Axsome Therapeutics, Inc. | 3 | $48 |
| Sumitomo Pharma America, Inc. | 3 | $48 |
| Boehringer Ingelheim | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| Exact Sciences | 3 | $45 |
| Merck | 2 | $38 |
| Corcept Therapeutics | 2 | $35 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Novartis | 1 | $23 |
| Assertio Therapeutics, Inc. | 1 | $17 |
| Corium, LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,246 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 101 | $131,400 |
| OzempicSemaglutide | 57 | $76,869 |
| JardianceEmpagliflozin | 54 | $61,319 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $46,663 |
| EliquisApixaban | 33 | $46,560 |
| JanuviaSitagliptin Phosphate | 28 | $27,602 |
| TrulicityDulaglutide | 14 | $15,822 |
| WegovySemaglutide | 11 | $14,464 |
| FarxigaDapagliflozin Propanediol | 11 | $14,052 |
| MyrbetriqMirabegron | 26 | $10,570 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,160 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,413 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,136 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $3,399 |
| Novolog FlexpenInsulin Aspart | 16 | $2,828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $416 | $147,222115 claims |
| Novo NordiskOzempic, Wegovy | $230 | $91,33368 claims |
| Boehringer IngelheimJardiance | $47 | $61,31954 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $110 | $57,95972 claims |
| PfizerEliquis | $2,380 | $46,56033 claims |
| MerckJanuvia | $38 | $27,60228 claims |
| AstraZenecaFarxiga | $63 | $14,05211 claims |
| Astellas Pharma US IncMyrbetriq | $152 | $10,57026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Fort Wayne
- Thomas KintanarFort Wayne$185K
- Brianna SerbusFort Wayne$174K
- Brian AdamsFort Wayne$173K
- Charles CoatsFort Wayne$38K
- Beulah PenumudiFort Wayne$38K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.